USA - NYSE:ALC - CH0432492467 - Common Stock
The current stock price of ALC is 77.12 USD. In the past month the price increased by 3.38%. In the past year, price decreased by -8.79%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 17.95 | 14.34B | ||
| SOLV | SOLVENTUM CORP | 12.78 | 13.16B | ||
| ALGN | ALIGN TECHNOLOGY INC | 13.94 | 9.77B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.23 | 5.12B | ||
| LNTH | LANTHEUS HOLDINGS INC | 8.78 | 3.56B | ||
| HAE | HAEMONETICS CORP/MASS | 15.46 | 3.57B | ||
| ICUI | ICU MEDICAL INC | 17.1 | 3.36B | ||
| XRAY | DENTSPLY SIRONA INC | 6.65 | 2.10B | ||
| UFPT | UFP TECHNOLOGIES INC | 26.06 | 1.73B | ||
| NEOG | NEOGEN CORP | 21.35 | 1.39B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.30B | ||
| EMBC | EMBECTA CORP | 4.95 | 844.60M |
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. The company is headquartered in Fribourg, Fribourg and currently employs 25,599 full-time employees. The company went IPO on 2019-04-09. The firm research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The firm operates in 60 countries and serves consumers and patients in over 140 countries.
ALCON INC
Rue Louis d'Affry 6
Fribourg FRIBOURG 1701 CH
CEO: David J. Endicott
Employees: 25000
Phone: 41589113800
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. The company is headquartered in Fribourg, Fribourg and currently employs 25,599 full-time employees. The company went IPO on 2019-04-09. The firm research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The firm operates in 60 countries and serves consumers and patients in over 140 countries.
The current stock price of ALC is 77.12 USD. The price decreased by -0.68% in the last trading session.
ALCON INC (ALC) has a dividend yield of 0.45%. The yearly dividend amount is currently 0.26.
ALC has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
The Revenue of ALCON INC (ALC) is expected to grow by 5.28% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ALCON INC (ALC) has a market capitalization of 38.54B USD. This makes ALC a Large Cap stock.
You can find the ownership structure of ALCON INC (ALC) on the Ownership tab.
ChartMill assigns a technical rating of 3 / 10 to ALC. When comparing the yearly performance of all stocks, ALC is a bad performer in the overall market: 77.44% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to ALC. ALC has an excellent profitability rating, but there are some minor concerns on its financial health.
Over the last trailing twelve months ALC reported a non-GAAP Earnings per Share(EPS) of 3. The EPS decreased by -0.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.7% | ||
| ROA | 3.42% | ||
| ROE | 4.85% | ||
| Debt/Equity | 0.23 |
20 analysts have analysed ALC and the average price target is 107.72 USD. This implies a price increase of 39.68% is expected in the next year compared to the current price of 77.12.
For the next year, analysts expect an EPS growth of 1.39% and a revenue growth 5.28% for ALC